The FDA found “unacceptable levels” of a cancer-causing impurity in limited testing using low-heat method of samples of heartburn medicines such as Zantac containing the ingredient ranitidine.

The U.S. Food and Drug Administration issued a warning letter to Becton Dickinson (BD) & Company that cited several violations of federal law.